Promising clinical results observed in the first 88 patients evaluated so far, confirming the safety and an important clinical benefit for patients Control of the infection at 3 months for ...
According to GlobalData, Phase II drugs for Resistant Pseudomonas aeruginosa Infections does not have sufficient ... include BX004 to treat cystic fibrosis (CF) and BX211 for the treatment of diabetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback